Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2022-11-09 Earnings Release
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers pour le troisième trimestre 2022
Earnings Release Classification · 98% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces an update on operational progress and financial results for the third quarter of 2022 ("RÉSULTATS FINANCIERS POUR LE TROISIÈME TRIMESTRE 2022"). It provides key highlights (clinical progress, cash position) and then details the financial results for the period ending September 30, 2022. This structure—a press release summarizing period-specific financial performance—is the definition of an Earnings Release (ER). Although it mentions a conference call to discuss the results, the document itself is the release containing the results summary, not just the announcement of the release (RPA) or the transcript (CT). Q3 2022
2022-11-09 French
NANOBIOTIX : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a table detailing the total number of shares and voting rights as of a specific date (October 31, 2022). This content directly corresponds to regulatory requirements for disclosing changes in the total share capital and voting rights, which is a specific type of regulatory disclosure. While it is a regulatory filing, the most specific category that covers disclosures about share capital structure and voting rights, especially when presented as a standalone monthly update, is often related to capital changes or major shareholding notifications. However, given the explicit focus on the total number of voting rights and shares, this aligns closely with the information required for major shareholding notifications or general capital structure updates. Since there isn't a specific code for 'Total Voting Rights Disclosure', I must choose the closest fit. 'MRQ' (Major Shareholding Notification) often encompasses changes in ownership thresholds, which is related, but this document reports the *total* capital base. 'SHA' (Share Issue/Capital Change) is also relevant. Given the context of mandatory monthly disclosure of the total capital base under AMF rules, this is a fundamental capital structure report. In many databases, such mandatory capital structure updates are classified under general share/capital change notifications. I will classify this as 'SHA' (Share Issue/Capital Change) as it reports the fundamental components of the capital structure, or potentially 'RNS' if it's considered a general regulatory announcement. Since it is a structured report on the capital base, 'SHA' is a strong candidate. However, looking at the definitions, 'MRQ' is for changes in *significant share ownership levels* (crossing thresholds), and 'SHA' is for *new share issues, stock splits, or other capital changes*. This document reports the total count, which is a prerequisite for threshold monitoring. Given the French context and the nature of this specific monthly disclosure, it is a mandatory regulatory filing that reports the current state of the capital base. If we consider the options, 'MRQ' is about *changes* in ownership, and 'SHA' is about *actions* changing the capital. This is a periodic report on the *current state*. In the absence of a perfect fit like 'Capital Structure Report', 'RNS' (Regulatory Filings - fallback) is safe, but 'SHA' often captures fundamental capital structure reporting. Let's re-evaluate based on the content: it's a disclosure of the total number of shares and voting rights. This is often required when thresholds are crossed, but here it is reported monthly regardless of crossing. This type of disclosure is often grouped with 'Major Shareholding Notification' (MRQ) or general capital updates. Given the explicit focus on the total number of shares and voting rights, which is the basis for threshold monitoring, MRQ is a plausible fit, but SHA covers the underlying capital structure itself. I will lean towards SHA as it reports the fundamental capital structure figures, which is a capital change/structure update, even if not triggered by a specific transaction. Alternatively, since it is a mandatory, periodic regulatory disclosure that doesn't fit the transactional nature of SHA or MRQ perfectly, RNS might be appropriate. However, the content is highly specific to capital structure. I will select SHA as the best fit for reporting the fundamental components of the capital structure.
2022-11-08 French
NANOBIOTIX nomme des experts de premier plan afin de former son conseil scientifique consultatif pour NBTXR3, son radioenhancer potentiel first-in-class
Board/Management Information Classification · 85% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces the appointment of experts to the Scientific Advisory Board for NBTXR3. This type of announcement, which details changes in advisory personnel and scientific strategy, is best classified as general corporate or management information, but specifically relates to the scientific/clinical direction. Since there is no specific category for 'Scientific Advisory Board Appointment', I must evaluate the closest fits: 1. **MANG (Board/Management Information):** This covers changes in the board of directors or senior management. While an advisory board is related, MANG usually implies governance/executive roles. 2. **RNS (Regulatory Filings):** This is the general fallback for miscellaneous announcements. 3. **LTR (Legal Proceedings Report):** Not applicable. Given the content focuses on forming a high-level scientific advisory body to guide clinical development, it strongly relates to the strategic direction and key personnel advising the company, making it conceptually closest to Board/Management Information (MANG), even if it's an advisory board rather than the statutory board. However, in the context of biotech filings, announcements about scientific advisors are often treated as general corporate news or regulatory updates if they don't fit a specific clinical trial update category. Since this is a press release announcing the formation of a key advisory group, and it is not a financial report (10-K, IR, ER), nor a proxy/governance document (DEF 14A, CGR), the most appropriate category among the provided options that captures personnel/governance structure changes is MANG, as it concerns the composition of a key governing/advisory body. I will assign MANG, recognizing it is a slight stretch but the best fit for personnel structure announcements.
2022-11-02 French
NANOBIOTIX participera à la Jefferies Healthcare Conference à Londres
Regulatory Filings Classification · 95% confidence The document is a press release announcing the participation of company executives (CEO and CFO) in an upcoming industry conference (Jefferies Healthcare Conference). It specifies the date, time, and format of their participation ('fireside chat'). This type of announcement, which informs investors about management's schedule for engaging with the market or analysts, is best classified as a general Investor Relations communication. Since it is not a formal financial report (like 10-K, IR, ER), nor a specific transaction (like DIV, DIRS, POS), nor a presentation attached for review (IP), the most appropriate category is the general 'Regulatory Filings' (RNS) as a catch-all for important, non-standard investor news, or potentially 'IP' if it were the presentation itself. Given the content is purely an announcement about *attendance* at an event, RNS serves as a strong fallback for general corporate news updates not covered elsewhere. However, since the content is specifically about management engaging with investors/analysts regarding company activities, and it is a short press release, RNS is the most suitable general category if a more specific one like 'IP' (Investor Presentation) is not applicable because the presentation material itself is not provided, only the announcement of attendance.
2022-10-31 French
NANOBIOTIX annoncera le 9 novembre 2022, ses resultats financiers pour le troisieme trimestre 2022
Earnings Release Classification · 98% confidence The document is a press release titled "NANOBIOTIX ANNONCERA LE 9 NOVEMBRE 2022, SES RÉSULTATS FINANCIERS POUR LE TROISIÈME TRIMESTRE 2022" (NANOBIOTIX WILL ANNOUNCE ITS FINANCIAL RESULTS FOR THE THIRD QUARTER 2022 ON NOVEMBER 9, 2022). It explicitly states the date the financial results will be published and details the subsequent conference call. This structure—announcing the upcoming release of periodic financial results and the associated call—is the defining characteristic of an Earnings Release (ER). Although it mentions the Q3 results, the document itself is the announcement, not the full report (IR) or the transcript (CT). Given the content, ER is the most appropriate classification. Q3 2022
2022-10-27 French
NANOBIOTIX conclut un accord définitif pour la restructuration du prêt octroyé par la Banque européenne d’investissement
Capital/Financing Update Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces that NANOBIOTIX has concluded a definitive agreement to restructure a loan/financing agreement with the European Investment Bank (EIB). This document details changes to debt repayment schedules, interest rates, and royalty payments, which are core components of corporate financing and capital structure management. This fits the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it specifically addresses a financing event.
2022-10-18 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.